BullishAgent BullishAgent Filings Market Economic Earnings Ratings IPOs ETFs Insiders Institutional Funds Screener
Sign in Register

OKYO

OKYO Pharma Limited NASDAQ Listed May 17, 2022
Healthcare ·Biotechnology ·GB · okyopharma.com
$1.62
Mkt Cap $62.2M
52w Low $1.32 14.8% of range 52w High $3.35
50d MA $1.63 200d MA $2.10
P/E (TTM) -13.8x
EV/EBITDA -6.9x
P/B
Debt/Equity 0.0x
ROE
P/FCF -27.7x
RSI (14)
ATR (14)
Beta -0.12
50d MA $1.63
200d MA $2.10
Avg Volume 211.9K
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
SIC Code
2836
CIK (SEC)
Phone
44 20 7495 2379
55 Park Lane · London, X0 W1K 1NA · GB
Data updated apr 26, 2026 5:14pm · Source: massive.com